Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Rating) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

NBRV opened at $2.42 on Monday. The company has a market capitalization of $64.42 million, a price-to-earnings ratio of -0.12 and a beta of 1.46. The company has a current ratio of 2.81, a quick ratio of 2.01 and a debt-to-equity ratio of 0.01. Nabriva Therapeutics has a 12-month low of $2.31 and a 12-month high of $35.00. The business’s fifty day simple moving average is $6.21 and its 200-day simple moving average is $6.93.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last issued its earnings results on Wednesday, August 3rd. The biotechnology company reported ($4.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.00) by $0.50. Nabriva Therapeutics had a negative net margin of 131.91% and a negative return on equity of 95.18%. The company had revenue of $9.19 million for the quarter, compared to analysts’ expectations of $8.53 million. On average, equities research analysts anticipate that Nabriva Therapeutics will post -17 earnings per share for the current fiscal year.

Institutional Trading of Nabriva Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in shares of Nabriva Therapeutics by 102.1% during the 2nd quarter. Renaissance Technologies LLC now owns 795,938 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 402,144 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Nabriva Therapeutics during the first quarter valued at about $179,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Nabriva Therapeutics in the 4th quarter valued at about $214,000. Institutional investors own 0.53% of the company’s stock.

Nabriva Therapeutics Company Profile

(Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Recommended Stories

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.